Abstract library

1993 results for "mixed tumor".
#719 Mixed Exocrine-Endocrine Pancreatic Tumors
Introduction: Mixed pancreatic tumors are very rare, characterized by association of exocrine (ductal or acinar) and endocrine components, and positivity for neuroendocrine (NE) markers in >30% of cells.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Pathology, grading, staging
Presenting Author: professor Claudio Pasquali
#685 A Small Mixed Adenocarcinoma and Neuroendocrine Tumor of the Duodenum with Multiple Liver Metastases
Introduction: Mixed adenocarcinoma and neuroendocrine cancers (MANECs) are rare specific type of tumors that are composed of two histologic components: a neuroendocrine carcinoma and an adenocarcinoma. There are only a few reports regarding MANEC of the stomach, colon and rectum in the literature.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr Nasim Valizadeh
#1087 Gastro-Entero-Pancreatic Mixed Adenoneuroendocrine Tumors. Report of Four Cases.
Introduction: Mixed adenoneuroendocrine carcinomas (MANECs) is an uncommon entity with ill-defined clinicopathologic characteristics.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Pathology, grading, staging
Presenting Author: Georgia Karayannopoulou
#2941 Mixed Urothelial and Neuroendocrine Carcinoma of the Urinary Bladder: Case Report and Literature Review
Introduction: Neuroendocrine tumors (NETs) comprise <1% of all bladder tumors,characterized by poor prognosis. These tumors may be either pure or impure, intermixed with urothelial carcinoma. There is currently no therapeutic consensus. We report the case of primary impure neuroendocrine carcinoma (NEC).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Mohammed Alaeddine Saidi
Authors: Saidi M A, Ghomari S, ...
#867 Mixed Adenoneuroendocrine Carcinoma (MANECs): A Rare and Challenging Subgroup of Neuroendocrine Neoplasia
Introduction: Mixed Adenoneuroendocrine Carcinomas (MANECs) are rare entities in which at least 30% of neoplastic cells are neuroendocrine in nature (WHO 2010 classification). They result either from two independent lesions that merge together or are unique lesions with different cell populations intermingled.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: Dr Conor Mosli Lynch
#2111 Biliary Neuroendocrine Tumors: A Retrospective Analysis of 28 Patients Since 1991
Introduction: Biliary neuroendocrine tumors represent less than 1% of all neuroendocrine tumors (NETs), and the related clinical study is limited.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Case reports
Presenting Author: Zhibo Zheng
Authors: Zheng Z, Chen C, Xie Y, Zheng C, ...
#544 Second Primary Tumor in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): Data From a Retrospective Observational Unicentric Study
Introduction: It is known that GEPNETs are associated with a high incidence of second primary tumors, especially in the context of inherited syndromes and synchronous injuries to the intestine.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Paula J Fonseca
#733 Analysis of Predictive Markers of Response to Chemotherapy in Microdissected Components of Mixed Neuroendocrine/non-Neuroendocrine Carcinomas
Introduction: Mixed neuroendocrine (NE)/non-NE carcinomas lack pathological or molecular prognostic or predictive markers.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Marco Volante
#666 Ability of Tumor Markers for Predicting Future Metastatic Disease in MEN-1 Patients with a Pancreatic Neuroendocrine Tumor
Introduction: The diagnostic value of tumor markers in the follow-up of MEN-1 patients with a pancreatic neuroendocrine tumor (pNET) is unclear.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Biomarkers
Presenting Author: MD Joanne De Laat
Keywords: MEN-1, tumor marker, pNET, SSA
#1606 Tumor Growth Rate to Assess Tumor Activity in Patients with Lung Neuroendocrine Tumors on Lanreotide Autogel: A Case-Series Analysis
Introduction: The slow-growing character of neuroendocrine tumors (NET) makes it difficult to assess treatment impact on tumor growth.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Clinical cases/reports
Presenting Author: Frank van Fraeyenhove